Pharmalink's Nefecon for IgA nephropathy receives FDA orphan drug designation
Links shared publicly online about this topic.
- 805total visits
Pharmalink's Nefecon for IgA nephropathy receives FDA orphan drug designation
Pharmalink AB, a privately held Swedish pharmaceutical company, has received orphan drug designation by the US Food and Drug Administration (FDA) for its product candidate Nefecon (PL-56) for patients with IgA nephropathy, also referred to as Berger's Disease. This program is presently in clinical development phase II.
View full resource at news-medical.net
Tags: Kidney Disease, Drug, Pharma, FDA, Oncology, News, Nephropathy
Most Recently Shared on October 13, 2010 at 10:50 am By:
Oncology News: Pharmalink's Nefecon for IgA nephropathy receives FDA orphan drug designation: Pharmalink AB, a pri... http://bit.ly/dqXxhy
Advertisement
